Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection.
The antibody response to SARS-CoV-2 has not yet fully defined, but the availability of sensitive and specific serological assays is crucial to observe the presence of specific antibodies against the human receptor binding domain (S-RBD) and high specificity ACE-2-binding antibodies or neutralizing antibodies (NT) in response to vaccines. Indeed, these peculiar antibodies should prevent viral interaction between RBD and Angiotensin-Converting Enzyme 2 (ACE2) receptor, located on surface of host cells. In this study, 72 samples from 37 hospitalized COVID-19 patients and 35 not-hospitalized patients were analyzed longitudinally. The detection of S-RBD and NT antibodies was carried out using CLIA tests. Hospitalized patients showed elevated serum levels of S-RBD (97.22%) and NT (77.78%) antibodies, differently, not-hospitalized, who were paucisymptomatic or asymptomatic patients, showed lower serum levels of S-RBD (65.71%) and NT (38.14%) antibodies. The results suggest that the NT serum level is strongly related to disease severity (p < 0.001) and to the serum level of S-RBD antibodies (p < 0.0001).
['Tomassetti|Flaminia|F|', 'Nuccetelli|Marzia|M|', 'Sarubbi|Serena|S|', 'Gisone|Francesca|F|', 'Ciotti|Marco|M|', 'Spinazzola|Francesco|F|', 'Ricotta|Cristina|C|', 'Cagnoli|Monica|M|', 'Borgatti|Monica|M|', 'Iannetta|Marco|M|', 'Andreoni|Massimo|M|', 'Calugi|Graziella|G|', 'Pieri|Massimo|M|', 'Bernardini|Sergio|S|']
D000328:Adult D000368:Aged D000369:Aged, 80 and over D000085962:Angiotensin-Converting Enzyme 2 D057134:Antibodies, Neutralizing D000914:Antibodies, Viral D000086382:COVID-19 D005260:Female D006801:Humans D007109:Immunity D008137:Longitudinal Studies D008297:Male D008875:Middle Aged D000086402:SARS-CoV-2 D012698:Serologic Tests
SARS-CoV-2 Neutralizing antibodies Vaccines S-RBD antibodies Serological tests